There is nothing more frustration that the current methods used by the FDA to approve drugs. The theory is great, but how it gets translated into our real world is killer, I mean a literal killer of men. The FDA wants assurances that before they approve a drug that it really works, or shows efficacy. [...]
A group of investigators, interested in the influence of lycopene on both the clinical and laboratory progression of advanced prostate cancer in men with hormone refractory prostate cancer, ran a small prospective Phase II pilot study. The researchers gave lycopene supplementation (15 mg) daily for 6 months to their trial subjects. They performed follow up [...]
How does the song go- "Suddenly, I'm not half the man I used to be.” That is a feeling that I have experienced and that I believe we all will experience. Nevertheless, we have to continue to plow through our treatments, pills, endless doctors appointments and, of course the co-pays. I do find that it [...]
Algeta ASA (OSE: ALGETA), has announced that it will begin to enroll US survivors into its Alsympca phase III trial evaluating Alpharadin (radium-223). Alpharadin is designed to be used as a treatment for bone metastases in prostate cancer survivors with hormone-refractory prostate cancer (HRPC). The announcement of the trial follows a successful end-of-phase II meeting [...]
Sure, we need more research about prostate cancer, but fortunately we also gain from research into other cancers. The commonly referred to breast cancer genes, BRCA1 and BRCA2 might also increase a man’s risk for developing an aggressive strain of prostate cancer. According to a report in Reuters, men with prostate cancer who also carry [...]